Skip to main content
Signal8
Launch Terminal

Voyager Therapeutics, Inc. (VYGR)

Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Voyager Therapeutics, Inc. logo

Voyager Therapeutics, Inc.

NASDAQ:VYGRHealthcare
-2.27%$1.72
AH$1.73+0.58%vs close
Mkt Cap$105.98M
Float50.31M
O/S61.62M
Vol
$ Vol
RVOL
Inst Own56.8%
Earnings
Dilution
Voyager Therapeutics, Inc. logoNASDAQ:VYGR$1.72-2.27%
Upcoming Catalysts
  • VY1706READOUT
    Cash runway at this date: 3mo
    Q1 2027~21w8-K
Phase Distribution
7 lead-sponsored trials·3 active·3 completed
Phase 12
Phase 1/21
Phase 22
Phase 31
Not applicable1
(4 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301)

    VP4896

    Alzheimer's Disease

    Enrollment
    555
    Start
    Sep 2005
    Primary Completion
    -
    Completion
    -
    NCT00231946
  • Phase 2
    Completed

    ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation

    Leuprolide acetate

    Alzheimer Disease

    Enrollment
    90
    Start
    Mar 2003
    Primary Completion
    Feb 2006
    Completion
    Feb 2006
    NCT00063310
  • Phase 2
    Completed

    Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study

    Leuprolide acetate

    Alzheimer Disease

    Enrollment
    90
    Start
    Dec 2003
    Primary Completion
    Mar 2007
    Completion
    Mar 2007
    NCT00076440
  • Phase 1/2
    Active, not recruiting

    VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease

    VY7523, Placebo Comparator

    Alzheimer's Disease (AD)

    Enrollment
    52
    Start
    Mar 2025
    Primary Completion
    Oct 2026
    Completion
    May 2027est.
    NCT06874621
  • Phase 1
    Withdrawn

    Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's Disease

    Intraparenchymal rAAV1 - (mi)RNA HTT

    Huntington Disease

    Enrollment
    0
    Start
    Jul 2021est.
    Primary Completion
    Dec 2024est.
    Completion
    Dec 2024est.
    NCT04885114
  • Phase 1
    Recruiting

    An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease

    VY1706 Low dose, VY1706 Mid dose

    Alzheimer s Disease

    Enrollment
    18
    Start
    Sep 2026
    Primary Completion
    Apr 2029est.
    Completion
    Apr 2029est.
    NCT07764146
  • Not applicable
    Recruiting

    Access Cannulation Trial II

    VenaSure

    Dialysis; Complications, Vascular Access Complication

    Enrollment
    100
    Start
    Apr 2025
    Primary Completion
    Mar 2027est.
    Completion
    Mar 2027est.
    NCT05490225
Search ClinicalTrials.gov for “Voyager Therapeutics”